Kheiron Biotech
Kheiron Biotech is an Argentine biotech firm specializing in elite equine SCNT cloning, CRISPR/Cas9 gene editing, stem cell therapy, and gene banking, serving high-net-worth polo professionals, sport-horse breeders, and select livestock and regenerative medicine clients.
- Company typePrivate
- Founded2013
- HeadquartersPilar, Argentina
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Kheiron Biotech does
Kheiron Biotech is an Argentine biotechnology company headquartered at Parque Austral in Pilar (Buenos Aires province), operating as a subsidiary of the Proinvesa Group. Founded in 2012, the firm specializes in advanced equine reproductive technologies — specifically somatic cell nuclear transfer (SCNT) cloning, CRISPR/Cas9-based gene editing, adult stem cell therapy, and cryogenic gene banking — with a flagship track record in cloning elite Argentine polo horses (e.g., Silvina Luna, Virolita, Birra, Lode, Levicu) and more recently jumping horses for European clients such as Zangersheide Belgium.
The company's core technology stack combines SCNT — the technique used to produce Dolly the sheep — with CRISPR/Cas9 editing that uses only native (wild-type) gene variants, producing edited animals that are genetically indistinguishable from those obtainable through conventional breeding. This non-transgenic architecture is engineered to sidestep GMO regulatory classification. Its scientific milestones include the world's first birth of eight simultaneous clones from a single animal (Virolita, February 2017) and the first CRISPR-Cas9 gene-edited equine embryos (December 2017, in collaboration with FLENI). R&D programs extend the platform into bovine myostatin editing (food industry), equine sport-performance optimization, and porcine organ humanization for xenotransplantation.
Commercially, Kheiron operates a high-touch, direct-sales B2B services model: veterinary teams travel to client farms to collect genetic material, with each project priced bespoke and not publicly disclosed. Revenue streams include professional-services cloning, gene editing, stem cell therapy, and a subscription-style gene banking product. Customers are concentrated in a narrow tier of high-net-worth polo professionals, elite breeders (notably Doña Sofía Polo as a flagship client and channel partner), and select international sport-horse registries. The company has no disclosed external venture funding, operates with 11–50 employees, and depends on earned media and academic partnerships (notably Acceligen/Recombinetics in the US and FLENI in Argentina) for both distribution and scientific validation.
Kheiron Biotech firmographics
Firmographics- Name
- Kheiron Biotech
- Legal name
- Kheiron Biotech
- Website
- https://kheiron-biotech.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Kheiron Biotech is an Argentine biotech firm specializing in elite equine SCNT cloning, CRISPR/Cas9 gene editing, stem cell therapy, and gene banking, serving high-net-worth polo professionals, sport-horse breeders, and select livestock and regenerative medicine clients.
- Ownership category
- akta.pro rank
Kheiron Biotech industry classification
Industry- Product category
- Animal Biotechnology Services
- NAICS
- Horses and Other Equine Production (112920), Veterinary Services (54194), All Other Animal Production (11299)
- SIC
- Agricultural Prod-Livestock & Animal Specialties (200), Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cloning & Advanced Reproductive Technologies Services (AFAEAJAL)
- akta.pro secondary industries
- Equine Reproduction Services (Embryo Transfer, AI, Fertility Clinics) (AFAEAGAK), Cell & Gene Therapy for Veterinary Regeneration (HLAMANAD), Reproduction, Breeding & Theriogenology (Large Animal/Equine) (HLAMABAG)
Keywords
Where Kheiron Biotech is headquartered
LocationHeadquarters
- HQ city
- Pilar
- HQ country
- Argentina
- HQ region
- Latin America
Offices1 record
Markets served
Kheiron Biotech business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D
Revenue model
- Equine Cloning Services: Reproduction services producing genetic replicas of top-performing horses including polo ponies, sport horses, and exceptional geldings. Revenue generated from specialized cloning procedures with premium pricing reflecting the advanced technology and high-value target animals.
- Gene Editing Services: CRISPR/Cas9-based gene editing to improve athletic performance, repair genetic defects, and enhance desirable traits in equines and livestock. Combined with cloning for accelerated genetic improvement.
- Stem Cell Therapy: Adult stem cell treatments for horses with chronic conditions, injuries, and arthritis. Treatment plans delivered through veterinary services at client facilities.
- Gene Banking: Cryogenic preservation services for genetic material storage, with cells maintained indefinitely for future cloning, gene mapping, or stem cell therapy applications.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Kheiron Biotech product offering
Product offeringCore offering
Kheiron Biotech is a biotechnology company that provides equine cloning via somatic cell nuclear transfer (SCNT), adult stem cell therapy for chronic equine injuries, and cryogenic gene banking services to preserve elite horse genetics. The company combines proprietary SCNT cloning with CRISPR/Cas9 gene editing under a "Precision Genetic Progress" methodology, enabling generation of genetic replicas of elite polo and sport horses and the introduction of desirable native genes without transgenic modifications. Services are delivered through mobile veterinary teams that travel to client farms and stables across Argentina and selected international clients.
Product overview
Kheiron Biotech is a biotechnology company specializing in equine cloning and advanced reproductive technologies. The company operates three core service products: Cloning (genetic replication of elite horses), Stem Cells (adult stem cell therapy for injuries and chronic conditions), and Gene Banking (cryogenic preservation of genetic material). The company also maintains active research and development programs in Gene Editing using CRISPR/Cas technology, Sport Performance improvements, Xenotransplantation (porcine organ generation), and Food Industry applications. The products form an integrated offering where gene banking enables future cloning, while gene editing enhances the genetic potential of cloned animals.
Differentiator
Problem solved
Functional benefit
Products and services
- Equine Cloning Somatic cell nuclear transfer (SCNT) cloning service that produces genetic replicas of top-performing polo ponies, sport horses, broodmares, and exceptional geldings for breeders, polo players, and equestrian professionals.
- Adult Stem Cell Therapy Adult stem cell treatment for horses addressing chronic conditions such as arthritis, tendon and ligament injuries, and fractures that have not responded to conventional therapies. Delivered through mobile veterinary teams at client facilities.
- Gene Banking Cryogenic preservation and storage of equine genetic material (cells) for indefinite future use in cloning, gene mapping, or stem cell therapy applications. Provides genetic insurance against loss through injury or death.
Quantifiable outcome
- First gene-edited equine embryos produced using CRISPR-Cas9 technology globally (December 2017)
- +3 more outcomes
Companies that use Kheiron Biotech
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
Kheiron Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Kheiron Biotech partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and flagship.
- Acceligen (Recombinetics Group)coreKheiron-Biotech, part of the Proinvesa Group, signed a partnership agreement with North American company Acceligen, a leader in gene editing belonging to the Recombinetics group. The alliance focuses on precision breeding projects combining Kheiron's cloning capabilities with Acceligen's gene editing expertise. The partnership aims to advance genetic improvement in livestock and potentially other species through combined technologies.
- FLENI (Fundación para la Lucha contra las Enfermedades Neurológicas Infantil)coreCollaboration with FLENI researchers to develop cloned equine embryos with improved genomes using CRISPR-Cas9 gene editing technology. This partnership produced the world's first gene-edited equine embryos, representing a major scientific breakthrough. FLENI contributes neurological and biomedical research expertise to the gene editing research.
- Doña Sofía Polo / Cabaña Doña SofíaflagshipMajor strategic customer and long-term collaborator in polo genetics. Doña Sofía is the largest customer, owning multiple clones (Lode, Levicu, Birra) and collaborating actively on breeding programs. Cabaña Doña Sofía - Genetic Innovation serves as a channel partner for genetic products and services.
- Proinvesa GroupflagshipKheiron Biotech is part of the Proinvesa Group, which includes affiliated companies Proinvet, PregAll, Taurón (bovine reproduction), Doña Sofía Polo, and Cabaña Doña Sofía. The group structure provides corporate backing, shared resources, and integrated distribution across equestrian and agricultural sectors.
Scale indicators4 records
Recent moves5 records
Expansion highlights5 records
Kheiron Biotech competitors and assessment
Company assessmentDirect peers
- Cryozootech: Pioneer French equine cloning company that produced the first cloned horse (Prometea, 2003). Historically the global benchmark in equine SCNT and a direct technical peer to Kheiron despite limited recent activity.
- Acceligen (Recombinetics): US-based gene editing company focused on livestock and aquaculture traits, and a current Kheiron partner. Directly comparable in applying CRISPR-based precision breeding for animal agriculture and aquaculture performance traits.
- Taurón (Proinvesa Group): Affiliated Proinvesa Group company focused on bovine reproduction and embryo transfer in Argentina. Operates within the same parent group as Kheiron and shares the equine/livestock reproduction customer base in the region.
- ViaGen Pets & Equine: US-based cloning service for horses, pets, and livestock. Most direct global competitor to Kheiron in commercial equine cloning, serving similar elite equestrian and sport-horse customers with comparable SCNT technology.
Broad incumbents
- Zoetis: Global animal health leader offering veterinary pharmaceuticals, biologics, diagnostics, and equine health products. Comparable in serving elite equine veterinarians and breeders, though Zoetis operates across all species rather than specializing in equine cloning.
- Genus plc: UK-listed global animal genetics company operating in bovine and porcine breeding, with active programs in gene-edited livestock (PRRSV-resistant pigs). A broad incumbent whose genetics platform and livestock distribution competes with Kheiron's bovine ambitions at scale.
- STgenetics: US-based bovine genetics and reproductive services company with significant investments in sexed semen, embryo transfer, and genomic selection. Provides comparable reproductive technology services for livestock at industrial scale.
Emerging players
- eGenesis: US biotech using CRISPR gene editing and cloning to develop human-compatible pig organs for transplantation. Comparable technology stack and end-market overlap with Kheiron's xenotransplantation R&D program.
- Revivicor (United Therapeutics): US-based gene editing and cloning company developing porcine organs for human xenotransplantation. Directly overlaps with Kheiron's R&D pipeline in humanized organ generation through SCNT + gene editing.
Others
- CRISPR Therapeutics: Clinical-stage human CRISPR gene editing company co-founded by Emmanuelle Charpentier. Not a direct competitor but an enabling/ecosystem peer given shared CRISPR IP origins and licensing relationships across the gene editing field.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Kheiron Biotech social profiles
Digital presenceKheiron Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kheiron Biotech leadership team
Management profileNumber of profiles
Profiles2 records
Kheiron Biotech funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kheiron Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kheiron Biotech
What does Kheiron Biotech do?
Kheiron Biotech is a biotechnology company that provides equine cloning via somatic cell nuclear transfer (SCNT), adult stem cell therapy for chronic equine injuries, and cryogenic gene banking services to preserve elite horse genetics. The company combines proprietary SCNT cloning with CRISPR/Cas9 gene editing under a "Precision Genetic Progress" methodology, enabling generation of genetic replicas of elite polo and sport horses and the introduction of desirable native genes without transgenic modifications. Services are delivered through mobile veterinary teams that travel to client farms and stables across Argentina and selected international clients.
Is Kheiron Biotech a public or private company?
Kheiron Biotech is a private company. It is classified as corporate owned and is currently operating.
When was Kheiron Biotech founded?
Kheiron Biotech was founded in 2013. It employs 11 to 50 people.
Where is Kheiron Biotech based?
Kheiron Biotech is headquartered in Pilar, Argentina, in the Latin America region.
How does Kheiron Biotech make money?
Four revenue lines are on record. Equine Cloning Services are the primary driver. The others are gene Editing Services, stem Cell Therapy and gene Banking.
Who are Kheiron Biotech's main competitors?
Direct peers on record are Cryozootech, Acceligen (Recombinetics), Taurón (Proinvesa Group) and ViaGen Pets & Equine. Broad incumbents are Zoetis, Genus plc and STgenetics. Emerging players are eGenesis and Revivicor (United Therapeutics). CRISPR Therapeutics is listed as an others.
Does Kheiron Biotech have an API?
No public API is recorded for Kheiron Biotech.
What industry is Kheiron Biotech in?
Kheiron Biotech's product category is Animal Biotechnology Services. Its primary akta.pro industry code is AFAEAJAL, Cloning & Advanced Reproductive Technologies Services, with a secondary code of AFAEAGAK, Equine Reproduction Services (Embryo Transfer, AI, Fertility Clinics). Its NAICS code is 112920 and its SIC code is 200.